Why Everyone Is Talking About Sirius XM Stock
Sirius XM generates recurring subscription revenue.
Berkshire Hathaway owns over one-third of the company.
However, Sirius XM faces challenges in expanding its reach.
10 stocks we like better than Sirius XM ›
Sirius XM (NASDAQ: SIRI) isn't often the center of attention, unlike some of its larger media peers, such as Netflix or Spotify.
But that's starting to change. The stock has dropped more than 40% from its highs (as of this writing) in the last 12 months, drawing interest from value hunters and long-term investors alike. And beneath the surface, there's more to the story than meets the eye.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
So why is everyone talking about Sirius XM stock right now? Here's what investors need to know.
Sirius XM operates a recurring revenue business model
Sirius XM operates a subscription-based satellite and streaming audio service. Its core business revolves around delivering a broad range of audio content, including music, sports, news, talk shows, and entertainment, to users across North America.
For a monthly fee -- depending on the plan -- subscribers gain access via factory-installed satellite radios in vehicles, the SiriusXM app, and smart speakers or other connected devices. Subscription revenue accounts for 76% of the company's total, making it the cornerstone of the business.
Sirius XM also generates revenue from advertising (20% of revenue), mainly from users who subscribe to the ad - supported content, primarily through Pandora and podcasting. The remaining 4% of revenue comes from licensing and other hardware sales.
In other words, Sirius XM is effectively a hybrid between legacy media and digital streaming, built around vehicle-based installations and habitual listening patterns.
Sirius XM has huge backing from smart investors
One reason the stock is making headlines is that Berkshire Hathaway owns 35.4% of Sirius XM -- a sizable bet, and not a recent one. Warren Buffett's team has been accumulating shares for years, suggesting long-term conviction.
While we can only speculate why Berkshire Hathaway has purchased such a massive stake in the company, there are at least two likely reasons.
First, Sirius XM's subscription business is sticky and recurring, with a loyal base of drivers who regularly tune in -- a strong foundation for cash generation, even amid modest subscriber losses.
And that brings us to the second point, which is Sirius XM's disciplined capital allocation framework. Historically, the media company has shown restraint in deploying excess capital, focusing on returning cash to shareholders through buybacks and dividends rather than on flashy acquisitions. In the last five years alone, it has repurchased $4 billion worth of stocks.
This mix of reliable cash flow and conservative capital use aligns well with Berkshire's investing philosophy.
A cheap stock, but not without risk
Sirius XM's recent poor stock performance has led to its attractive valuation. As of the time of writing, it has a price-to-sales (P/S) ratio of 1, down from its five-year high of 3. Comparatively, Spotify trades at a P/S ratio of 8.3 times.
The stock looks cheap, but there are real challenges:
Sirius XM posted a net loss in 2024, a reversal from its history of profitability. While the loss was primarily due to one-time restructuring and impairment charges, it suggests that the company faces some challenges going forward.
Revenue has declined from $9 billion in 2022 to $8.7 billion in 2024, signaling saturation in its core market.
Paid subscribers are slipping -- down from 34.9 million in 2019 to 33.2 million in 2024.
While Sirius XM remains highly profitable on the cash flow level, having generated $1 billion in free cash flow in 2024, its declining revenue suggests that it is struggling to compete against younger peers like Spotify in expanding its reach.
Sirius XM is pinning hopes on its advertising and podcast business, including its acquisition of Pandora. But that turnaround remains a work in progress. Pandora remains far behind the category leaders, and competition in podcasting is fierce. Worse still, Panda's monthly active users have been declining over the last five years as well, down from 63.5 million to 43.3 million.
In other words, while Sirius XM still has a loyal base of subscribers, this cohort is contracting over the years, with no sign of a turnaround anytime soon.
What does it all mean?
Sirius XM is a paradox: It's not growing, but it's still throwing off tons of cash. And while its audio subscription business model looks dated, it has the backing of one of the most respected investors of our time.
Whether Sirius is a value trap or a misunderstood opportunity depends on investors' perspective. The company faces real risks, but if it can stabilize its subscriber base and revitalize Pandora, there could be meaningful upside from here.
Either way, it's one worth keeping on your radar.
Should you invest $1,000 in Sirius XM right now?
Before you buy stock in Sirius XM, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sirius XM wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!*
Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
27 minutes ago
- CBC
Ontario-made alcohol gets largest tax cut in decades
Ontario's new alcohol tax cut, which is intended to support local producers, took effect last week. The province says the move will make the industry more competitive amid U.S. tariffs and growing economic pressures.
Globe and Mail
28 minutes ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CTV News
an hour ago
- CTV News
Scott Moe speaks out against AI ‘deepfakes' of him circulating online
Saskatchewan Premier Scott Moe listens to a question from the media during the 2025 summer meetings of Canada's Premiers at Deerhurst Resort in Huntsville, Ont., on Wednesday, July 23, 2025. THE CANADIAN PRESS/Nathan Denette Saskatchewan Premier Scott Moe says his government is doing whatever it can to track down the creators of so-called 'deepfakes' of him and other prominent figures. Moe's likeness, including his voice, has been used in online video ads for cryptocurrency schemes that he says he would never endorse. The premier says on his official social media that some of the videos, which are created with artificial intelligence, feature him and others, including Prime Minister Mark Carney. Moe says his government is doing its best to find the people behind the videos, but adds it can be difficult to prevent the scams. It's not the first time Moe's image has been used to market the scams — he first acknowledged them in March. Saskatchewan's consumer watchdog has been issuing warnings about the impersonation scams and urges people not to send money to companies that aren't registered in the province. This report by The Canadian Press was first published Aug. 4, 2025.
